Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00174369 · ClinicalTrials.gov registry record · Phase 2
MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT00174369 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 34 participants.
The verdict
NCT00174369, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with non-small cell lung cancer. PD-325901 will be given by mouth as a pill twice a day, CT scans will be done and biopsies of a tumor and a blood sample will be taken before treatment to examine the how genes affect tumor response to the study medication. Blood samples will be taken to measure the amount of drug in the blood.
Interventions
- DRUG PD-0325901
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2005-11 |
| Est. Completion | 2007-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00174369
The ClinicalTrials.gov registry entry for NCT00174369 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PD-0325901 is the first listed.
NCT00174369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00174369 about?
NCT00174369 is a clinical study titled "MEK Inhibitor PD-325901 To Treat Advanced Non-Small Cell Lung Cancer". MEK is a critical member of the MAPK pathway involved in growth and survival of cancer cells. PD-325901 is a new drug designed to block this pathway and kill cancer cells. The purpose of this study is to study the effectiveness of PD-325901 in patients with non-small cell lung cancer. PD-325901 will...
What is the current status of trial NCT00174369?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2005-11. Estimated completion is 2007-06.
What interventions are being tested in trial NCT00174369?
The interventions under investigation include: PD-0325901 (DRUG).
Who is sponsoring clinical trial NCT00174369?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.